Synerk has independent intellectual property rights, the world's advanced liver delivery technology platform, and is developing a variety of different extrahepatic delivery technologies. The pipeline in research includes cardiovascular diseases, metabolic diseases, rare diseases, central nervous system diseases, etc. There are many FIC pipeline products.

siRNA-targeted therapy is an emerging therapeutic field after small molecules and antibodies, an outstanding advantage of RNA-targeted therapy is that the identification of drug candidates only needs to determine the target area related to the disease process in RNA, and for any target gene, the corresponding small nucleic acid can be designed to regulate its expression, so RNA therapy has great application potential in traditional undruggable diseases or targets, bringing revolutionary breakthr

The partnership will combine Sciwind's expertise in disease biology and clinical development with Synerk's proprietary siRNA delivery technology platform and extensive experience in siRNA innovative drug development

化学修饰与递送系统创新已成为了目前小核酸企业亟待突破的瓶颈及未来的技术发展方向